文献速递肝病消化道肿瘤与早癌

抑制素1在小鼠及人肝细胞癌和胆管癌细胞中抑制肝癌发生

Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.
PubMed 文献 · Hepatology · 2017-01-31

抑制素1(PHB1)在多数人肝细胞癌(HCC)和胆管癌(CCA)中表达下调,其表达与HCC和CCA细胞生长呈负相关。PHB1与MATα1相互正向调节,负向调节c-MYC、MAFG和c-MAF表达,并与MAX形成异二聚体结合E-box抑制启动子活性。8月龄肝特异性Phb1敲除小鼠全部发生HCC,1只发生CCA。

要点

  • PHB1在正常人肝细胞和胆管上皮细胞高表达,在多数人HCC和CCA中下调。
  • PHB1与MATα1相互正向调节,负向调节c-MYC、MAFG和c-MAF表达。
  • 8月龄肝特异性Phb1敲除小鼠全部发生HCC,1只发生CCA。

核心结论

  • PHB1在多数人HCC和CCA中下调,与MAX形成异二聚体抑制E-box并正向调节MAT1A,同时抑制c-MYC、MAFG和c-MAF表达;在小鼠中,PHB1表达降低易感胆汁淤积诱导的CCA。

研究设计与样本

  • 研究检测了人HCC和CCA细胞及组织中PHB1、MATα1与c-MYC等的表达与相互作用,并使用肝特异性Phb1敲除小鼠、Phb1杂合子及Phb1 flox小鼠进行体内观察。

主要发现

  • PHB1在正常人肝细胞和胆管上皮细胞高表达,在多数人HCC和CCA中下调;在HCC和CCA细胞中PHB1表达与生长呈负相关。
  • PHB1与MAT1A相互正向调节各自表达,PHB1负向调节c-MYC、MAFG和c-MAF表达。
  • PHB1和MATα1均与MAX形成异二聚体,结合E-box元件并抑制E-box启动子活性。
  • PHB1启动子含抑制性E-box元件,在非恶性胆管细胞和非癌组织中主要被MAX、MNT和MATα1占据,而在癌细胞和人HCC/CCA中转换为c-MYC、c-MAF和MAFG占据。
  • 所有8月龄肝特异性Phb1敲除小鼠均发生HCC,其中1只发生CCA;5月龄Phb1杂合子(而非Phb1 flox小鼠)出现异常胆管增生,1只在左和中间胆管结扎后3.5个月发生CCA。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Prohibitin 1 (PHB1) is best known as a mitochondrial chaperone, and its role in cancer is conflicting. Mice lacking methionine adenosyltransferase α1 (MATα1) have lower PHB1 expression, and we reported that c-MYC interacts directly with both proteins. Furthermore, c-MYC and MATα1 exert opposing effects on liver cancer growth, prompting us to examine the interplay between PHB1, MATα1, and c-MYC and PHB1's role in liver tumorigenesis. We found that PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells and down-regulated in most human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). In HCC and CCA cells, PHB1 expression correlates inversely with growth. PHB1 and MAT1A positively regulate each other's expression, whereas PHB1 negatively regulates the expression of c-MYC, MAFG, and c-MAF. Both PHB1 and MATα1 heterodimerize with MAX, bind to the E-box element, and repress E-box promoter activity. PHB1 promoter contains a repressive E-box element and is occupied mainly by MAX, MNT, and MATα1 in nonmalignant cholangiocytes and noncancerous tissues that switched to c-MYC, c-MAF, and MAFG in cancer cells and human HCC/CCA. All 8-month-old liver-specific Phb1 knockout mice developed HCC, and one developed CCA. Five-month-old Phb1 heterozygotes, but not Phb1 flox mice, developed aberrant bile duct proliferation; and one developed CCA 3.5 months after left and median bile duct ligation. Phb1 heterozygotes had a more profound fall in the expression of glutathione synthetic enzymes and higher hepatic oxidative stress following left and median bile duct ligation. CONCLUSION: We have identified that PHB1, down-regulated in most human HCC and CCA, heterodimerizes with MAX to repress the E-box and positively regulates MAT1A while suppressing c-MYC, MAFG, and c-MAF expression; in mice, reduced PHB1 expression predisposes to the development of cholestasis-induced CCA. (Hepatology 2017;65:1249-1266).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fan W, Yang H, Liu T, et al. Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology. 2017. PMID: 27981602. doi:10.1002/hep.28964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。